Sunovion announced Wednesday it has entered into an exclusive U.S. license agreement with Swiss drugmaker Novartis for three of its lung disease medicines.
Sunovion now has the exclusive rights to market Utibron Neohaler, Seebri Neohaler, and Arcapta Neohaler in the U.S., and plans to bring them to market in 2017. The licensing means the Marlborough company now has the broadest portfolio of chronic obstructive pulmonary disease treatments in the U.S. and can offer treatment options to people with all stages of the disease. Novartis will remain the manufacturer of the medicines, under the terms of the agreement.Â
Sunovion’s existing portfolio includes Brovana, which can treat breathing problems; a long-acting beta agonist for more severe symptoms; and SUN-101/eFlow, a long-term maintenance breathing therapy for which Sunovion filed a new drug application to the U.S. Food and Drug Administration this past July. Financial details were not disclosed.
